Best Columvi (Glofitamab) Medicine in India

Columvi (Glofitamab) is a targeted immunotherapy used to treat certain types of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. It is a bispecific antibody that helps the immune system recognize and destroy abnormal B-cells, making it an important treatment option for eligible patients whose cancer has returned or stopped responding to previous therapies.

Columvi (Glofitamab) is administered by a healthcare professional through an intravenous infusion according to a specific treatment schedule. The dose is gradually increased at the beginning of treatment to reduce the risk of serious reactions. Your doctor will determine the appropriate treatment schedule based on your condition and response to therapy. Close medical monitoring is required during treatment.

Common side effects of Columvi (Glofitamab) may include cytokine release syndrome (CRS), fever, fatigue, muscle and joint pain, rash, nausea, diarrhea, and low blood cell counts. Serious immune-related reactions and nervous system problems can also occur. Inform your doctor about your medical history and all medicines or supplements you are taking. Seek immediate medical attention if you develop high fever, chills, difficulty breathing, confusion, severe dizziness, or other unusual symptoms during or after treatment.

Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Columvi (Glofitamab) is used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after previous treatments have stopped working or the cancer has returned. It helps the immune system identify and attack abnormal B-cells by bringing T-cells into close contact with lymphoma cells. This can reduce cancer cell growth and help control the progression of the disease.

Some side effects of Columvi (Glofitamab) may improve as your body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Columvi (Glofitamab)

Columvi (Glofitamab) is administered by a healthcare professional through an intravenous infusion. Treatment begins with gradually increasing doses before the recommended treatment dose is given, helping reduce the risk of cytokine release syndrome. Your doctor will determine the treatment schedule based on your condition and response to therapy. Close medical monitoring is required, particularly during the initial doses.

Columvi (Glofitamab) is a bispecific antibody that connects T-cells with CD20-positive B-cells, including abnormal lymphoma cells. By bringing T-cells close to the cancer cells, it activates the immune system to attack and destroy them. This helps reduce lymphoma cells and may slow the progression of diffuse large B-cell lymphoma (DLBCL).

• Keep the unopened vial refrigerated between 2°C and 8°C.
• Retain the vial in its original carton to protect it from light.
• Do not freeze or shake the vial during storage.
• After dilution, the solution can be refrigerated at 2°C to 8°C for up to 64 hours or kept at room temperature up to 25°C for 4 hours.

Alcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Columvi (Glofitamab).

Pregnancy CONSULT YOUR DOCTOR

Columvi (Glofitamab) may harm an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant.

Breastfeeding CONSULT YOUR DOCTOR

Consult your doctor before breastfeeding during treatment with Columvi (Glofitamab), as the potential risk to the infant is not fully known.

Driving CONSULT YOUR DOCTOR

Columvi (Glofitamab) may cause dizziness, fatigue, or nervous system effects. Avoid driving if these symptoms affect your alertness or coordination.

Kidney CAUTION

Inform your doctor if you have kidney problems before starting treatment with Columvi (Glofitamab). Your doctor will determine the appropriate treatment and monitoring.

Liver CAUTION

Tell your doctor if you have liver problems. Liver function may be monitored during treatment with Columvi (Glofitamab).

• Attend all scheduled appointments and follow your doctor's treatment schedule, especially during the initial doses of Columvi (Glofitamab).
• Report fever, chills, low blood pressure, rapid heartbeat, breathing difficulties, or other symptoms that may indicate cytokine release syndrome (CRS).
• Contact your doctor immediately if you experience confusion, severe dizziness, difficulty speaking, loss of coordination, or other nervous system changes.
• Inform your doctor about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible interactions.
• Do not change, interrupt, or stop Columvi (Glofitamab) treatment without your doctor's advice.
• Read More About - Columvi (Glofitamab) from Pharma Five.

Pharma Five, can support patients in arranging the import of Columvi (Glofitamab) in small quantities for personal use. For this purpose, the applicant is required to submit an application in Form 12A, accompanied by a prescription issued by a Registered Medical Practitioner (RMP).

Through its pharmaceutical consultancy and facilitation services, Pharma Five helps patients obtain access to Columvi (Glofitamab) and other specialized medicines through professional import assistance. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.